Sign inJoin waitlistJoin the waitlist

EB

Ellen Basu

(Pediatric Residency Program Director) · New York Presbyterian Hospital

Credentials: · · · · · ·

History

(Pediatric Residency ) Residency · New York Presbyterian Hospital
Present

Pediatric Hematology Oncology
Boston Children's Hospital
2007–2010
Pediatrics
Boston Children's Hospital
2004–2007
Albert Einstein College of Medicine
2000–2004

Research

Extracellular Vesicle and Particle Biomarkers Define Multiple Human Cancers
Cell · 2020 · 1,025 citations
Prospective pan-cancer germline testing using MSK-IMPACT informs clinical translation in 751 patients with pediatric solid tumors
Nature Cancer · 2021 · 146 citations
Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG)
Neuro-Oncology · 2022 · 112 citations

SM
Shakeel Modak
43 papers
BK
Brian Kushner
37 papers
SR
Stephen Roberts
32 papers
KK
Kim Kramer
26 papers
NC
Nai-Kong Cheung
17 papers
MQ
Michael La Quaglia
10 papers · 1 as a fellow
SW
Suzanne Wolden
9 papers
Neeta Pandit-Taskar
8 papers · 5 as a fellow
Yasmin Khakoo
4 papers
AP
Anita Price
3 papers
Dana Casey
3 papers · 1 as a resident
DF
Danielle Friedman
3 papers · 1 as a fellow

Clinical trials

Local Injection of Pain Medication to Reduce Pain After Bone Marrow Procedures in Pediatric Neuroblastoma Patients
Principal investigator · Completed
Memorial Sloan Kettering Cancer Center
2016–2019
Humanized 3F8 Monoclonal Antibody (Hu3F8) in Patients With High-Risk Neuroblastoma and GD2-Positive Tumors
Principal investigator · Completed · Phase 1
Memorial Sloan Kettering Cancer Center
2011–2023
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
Principal investigator · Recruiting · Phase 2
Memorial Sloan Kettering Cancer Center
2006–2027
A Study of Therapeutic Iobenguane (131-I) and Vorinostat for Recurrent or Progressive High-Risk Neuroblastoma Subjects
Site PI · Unknown · Phase 2
Jubilant DraxImage Inc.
2019–2025